Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gadopentetate dimeglumine
Drug ID BADD_D00991
Description A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)
Indications and Usage For use with magnetic resonance imaging (MRI) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues as well as lesions with abnormal vascularity in the head and neck. Also used to facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart).
Marketing Status Prescription
ATC Code V08CA01
DrugBank ID DB00789
KEGG ID D01707
MeSH ID D019786
PubChem ID 131751658
TTD Drug ID D0RQ2W
NDC Product Code 50419-188
Synonyms Gadolinium DTPA | DTPA, Gadolinium | Gadolinium Diethylenetriaminepenta-acetic Acid | Diethylenetriaminepenta-acetic Acid, Gadolinium | Gadolinium Diethylenetriaminepenta acetic Acid | Gadopentetic Acid | Gd-DTPA | Gd DTPA | Gadolinium DTPA Disodium Salt | Magnograf | Magnograf Enteral | Gadopentetate Dimeglumine | Dimeglumine, Gadopentetate | Gadolinium DTPA Dimeglumine Salt | Gadolinium DTPA Dimeglumine | Dimeglumine, Gadolinium DTPA | Magnevist | Magnevist Enteral
Chemical Information
Molecular Formula C51H82O21
CAS Registry Number 55466-01-8
SMILES CC(=CC1CC(C2C3CCC4C5(CCC(C(C5CCC4(C36CC2(O1)OC6)C)(C)C)OC7C(C(C(CO7)O)OC8C(C(C(C (O8)CO)O)O)OC9C(C(C(CO9)O)O)O)OC1C(C(C(CO1)O)O)O)C)(C)O)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Respiratory distress22.02.01.012--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Salivary hypersecretion07.06.01.009--Not Available
Seizure17.12.03.001--
Sneezing22.02.05.011--
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.02.05.034; 19.19.02.002; 17.02.08.003--Not Available
Syncope02.01.02.008; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.007--Not Available
Teething07.09.05.005--Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Throat irritation22.02.05.013; 07.05.03.004--Not Available
Thrombophlebitis24.01.02.001--Not Available
Tremor17.01.06.002--
Urinary incontinence20.02.02.010; 17.05.01.008--
Urticaria23.04.02.001; 10.01.06.001--
Vasodilatation24.03.02.003; 23.06.05.006--Not Available
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Hypoacusis04.02.01.006--
Localised oedema14.05.06.009; 08.01.07.011; 02.05.04.006--
Deep vein thrombosis24.01.02.003--Not Available
Renal impairment20.01.03.010--Not Available
Nephrogenic systemic fibrosis15.06.01.009; 10.04.02.007; 23.03.02.012; 20.01.01.004--Not Available
Acute kidney injury20.01.03.016--
The 3th Page    First    Pre   3    Total 3 Pages